Oligonucleotide Synthesis Market 2019-2023 | Increasing Research Activities in the Pharmaceutical and Biotechnology Sectors to Boost Growth | Technavio

LONDON–(BUSINESS WIRE)–#Healthcare–Technavio has been monitoring the oligonucleotide synthesis market and it is poised to grow by USD 1.02 bn during 2019-2023, progressing at a CAGR of 10% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Increasing research activities in the pharmaceutical and biotechnology sectors has been instrumental in driving the growth of the market. However, diversity in oligonucleotide molecules might hamper market growth. Request a free sample report

Oligonucleotide Synthesis Market 2019-2023: Segmentation

Oligonucleotide Synthesis Market is segmented as below:

End-user

• Pharmaceutical and Biotechnology Companies
• Research and Academic Institutes
• Diagnostic Laboratories
• Hospitals

Geographic segmentation

• North America
• Europe
• Asia
• ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR32105

Oligonucleotide Synthesis Market 2019-2023: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our oligonucleotide synthesis market report covers the following areas:

• Oligonucleotide Synthesis Market size
• Oligonucleotide Synthesis Market trends
• Oligonucleotide Synthesis Market industry analysis

This study identifies increasing focus on R&D of new oligonucleotide therapeutics as one of the prime reasons driving the oligonucleotide synthesis market growth during the next few years.

Oligonucleotide Synthesis Market 2019-2023: Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the oligonucleotide synthesis market, including some of the vendors such as Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc. and Thermo Fisher Scientific Inc. Backed with competitive intelligence and benchmarking, our research reports on the oligonucleotide synthesis market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Oligonucleotide Synthesis Market 2019-2023: Key Highlights

• CAGR of the market during the forecast period 2019-2023
• Detailed information on factors that will assist oligonucleotide synthesis market growth during the next five years
• Estimation of the oligonucleotide synthesis market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the oligonucleotide synthesis market
• Analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of oligonucleotide synthesis market vendors

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]
Website: www.technavio.com/